• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

评论“一种用于治疗艰难梭菌感染的小分子抗病毒药物”。

Comment on "A small-molecule antivirulence agent for treating Clostridium difficile infection".

机构信息

Molecular Structure & Function, The Hospital for Sick Children, Toronto, Ontario M5G 0A4, Canada.

Department of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada.

出版信息

Sci Transl Med. 2016 Dec 21;8(370):370tc2. doi: 10.1126/scitranslmed.aad8926.

DOI:10.1126/scitranslmed.aad8926
PMID:28003550
Abstract

New insights into the mechanism of action of ebselen, a small-molecule antivirulence agent that reduces disease pathology in a mouse model of Clostridium difficile infection, suggest a different molecular target may be responsible for its efficacy.

摘要

深入了解小分子抗毒剂依布硒啉的作用机制，该药物可降低艰难梭菌感染小鼠模型的疾病病理，这表明其疗效可能与不同的分子靶标有关。

相似文献

1
Comment on "A small-molecule antivirulence agent for treating Clostridium difficile infection".评论“一种用于治疗艰难梭菌感染的小分子抗病毒药物”。
Sci Transl Med. 2016 Dec 21;8(370):370tc2. doi: 10.1126/scitranslmed.aad8926.
2
Response to Comment on "A small-molecule antivirulence agent for treating Clostridium difficile infection".回复对“一种治疗艰难梭菌感染的小分子抗病毒药物”的评论。
Sci Transl Med. 2016 Dec 21;8(370):370tr2. doi: 10.1126/scitranslmed.aaf3410.
3
A small-molecule antivirulence agent for treating Clostridium difficile infection.一种用于治疗艰难梭菌感染的小分子抗毒力剂。
Sci Transl Med. 2015 Sep 23;7(306):306ra148. doi: 10.1126/scitranslmed.aac9103.
4
Small Molecules Take A Big Step Against Clostridium difficile.小分子药物在对抗艰难梭菌方面取得重大进展。
Trends Microbiol. 2015 Dec;23(12):746-748. doi: 10.1016/j.tim.2015.10.009. Epub 2015 Nov 5.
5
Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections.酰基缩酚肽类抗生素作为一种抗艰难梭菌复发性感染的潜在治疗药物。
Future Microbiol. 2016 Sep;11:1179-89. doi: 10.2217/fmb-2016-0064. Epub 2016 Aug 22.
6
Small animal models for the study of Clostridium difficile disease pathogenesis.用于研究艰难梭菌发病机制的小动物模型。
FEMS Microbiol Lett. 2014 Mar;352(2):140-9. doi: 10.1111/1574-6968.12367. Epub 2014 Jan 7.
7
Modeling new immunoregulatory therapeutics as antimicrobial alternatives for treating Clostridium difficile infection.将新型免疫调节疗法作为治疗艰难梭菌感染的抗菌替代方案进行建模。
Artif Intell Med. 2017 May;78:1-13. doi: 10.1016/j.artmed.2017.05.003. Epub 2017 May 9.
8
Clostridium difficile infection: New insights into therapeutic options.艰难梭菌感染：治疗选择的新见解
Crit Rev Microbiol. 2016 Sep;42(5):773-9. doi: 10.3109/1040841X.2015.1027171. Epub 2015 May 8.
9
[Comment on the article by E. Zemanova et al: "Clostridium difficile infection associated with pseudomembranous colitis in district hospitals].[对E. 泽马诺娃等人文章《地区医院中艰难梭菌感染与假膜性结肠炎的关联》的评论]
Vnitr Lek. 2003 Aug;49(8):588-9.
10
Clostridioides (Clostridium) difficile infection: current and alternative therapeutic strategies.艰难梭菌（梭状芽孢杆菌）感染：当前和替代治疗策略。
Future Microbiol. 2018 Mar;13:469-482. doi: 10.2217/fmb-2017-0203. Epub 2018 Feb 21.

引用本文的文献

1
Identification of genomic variants associated with colorectal cancer heredity in indigenous populations of the Amazon.亚马逊地区原住民中与结直肠癌遗传相关的基因组变异的鉴定。
Sci Rep. 2025 Apr 26;15(1):14616. doi: 10.1038/s41598-025-87401-0.
2
Antibacterial Activity of Ebselen.埃斯硒啉的抗菌活性。
Int J Mol Sci. 2023 Jan 13;24(2):1610. doi: 10.3390/ijms24021610.
3
Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives.外毒素靶向药物模式作为抗生素替代品。
ACS Infect Dis. 2022 Mar 11;8(3):433-456. doi: 10.1021/acsinfecdis.1c00296. Epub 2022 Jan 31.
4
: innovations in target discovery and potential for therapeutic success.: 目标发现的创新和治疗成功的潜力。
Expert Opin Ther Targets. 2021 Nov;25(11):949-963. doi: 10.1080/14728222.2021.2008907. Epub 2021 Dec 2.
5
Anti-virulence strategies for infection: advances and roadblocks.抗感染的抗毒力策略：进展与障碍。
Gut Microbes. 2020 Nov 9;12(1):1802865. doi: 10.1080/19490976.2020.1802865.
6
Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.采用自组装单分子层解吸电离质谱法评价 SARS-CoV-2 3C 样蛋白酶抑制剂。
Antiviral Res. 2020 Oct;182:104924. doi: 10.1016/j.antiviral.2020.104924. Epub 2020 Sep 5.
7
Characterization of Aminobenzylphenols as Protein Disulfide Isomerase Inhibitors in Glioblastoma Cell Lines.鉴定氨基苯甲基苯酚类化合物对神经胶质瘤细胞系蛋白二硫键异构酶的抑制作用。
J Med Chem. 2020 Sep 24;63(18):10263-10286. doi: 10.1021/acs.jmedchem.0c00728. Epub 2020 Sep 11.
8
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.临床药物依布硒啉可减轻 CDI 抗生素治疗后小鼠的炎症反应并促进其微生物组恢复。
Cell Rep Med. 2020 Apr 21;1(1). doi: 10.1016/j.xcrm.2020.100005.
9
Recent advances in the treatment of using biotherapeutic agents.使用生物治疗药物进行治疗的最新进展。 （原句“Recent advances in the treatment of using biotherapeutic agents.”表述不完整，推测完整句子可能是“Recent advances in the treatment of [某种疾病等] using biotherapeutic agents.” 这里按现有内容翻译）
Infect Drug Resist. 2019 Jun 10;12:1597-1615. doi: 10.2147/IDR.S207572. eCollection 2019.
10
Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota.靶向宿主的尼氯硝唑抑制艰难梭菌的毒力，防止小鼠发病，而不破坏肠道微生物群。
Nat Commun. 2018 Dec 7;9(1):5233. doi: 10.1038/s41467-018-07705-w.